Press Releases

Mar 31, 2016 • 7:05 AM EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update

Mar 10, 2016 • 7:35 AM EST Matinas BioPharma to Present at the 28th Annual ROTH Conference

Mar 7, 2016 • 7:05 AM EST Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections

Feb 10, 2016 • 8:05 AM EST Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology

Feb 8, 2016 • 7:05 AM EST Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B

Feb 1, 2016 • 7:35 AM EST Matinas BioPharma Receives FDA Clearance to Initiate Phase 1 Clinical Study of MAT2501 for the Treatment of Non-Tuberculous Mycobacterium Infections

Jan 5, 2016 • 7:01 AM EST Matinas BioPharma to Present at Biotech Showcase™ on January 12, 2016

Jan 4, 2016 • 7:05 AM EST Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501

Dec 17, 2015 • 7:05 AM EST Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA

Dec 14, 2015 • 7:05 AM EST Matinas BioPharma’s Lead Antibacterial Development Candidate MAT2501 Granted QIDP Designation by U.S. FDA